CA2879595C - Derivatives of azaindazole or diazaindazole type for treating pain - Google Patents

Derivatives of azaindazole or diazaindazole type for treating pain Download PDF

Info

Publication number
CA2879595C
CA2879595C CA2879595A CA2879595A CA2879595C CA 2879595 C CA2879595 C CA 2879595C CA 2879595 A CA2879595 A CA 2879595A CA 2879595 A CA2879595 A CA 2879595A CA 2879595 C CA2879595 C CA 2879595C
Authority
CA
Canada
Prior art keywords
charom
pyrazolo
pyridin
group
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2879595A
Other languages
English (en)
French (fr)
Other versions
CA2879595A1 (en
Inventor
Pierre Sokoloff
Frederic Cachoux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CA2879595A1 publication Critical patent/CA2879595A1/en
Application granted granted Critical
Publication of CA2879595C publication Critical patent/CA2879595C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2879595A 2012-07-27 2013-07-29 Derivatives of azaindazole or diazaindazole type for treating pain Active CA2879595C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305922.2 2012-07-27
EP12305922.2A EP2689778A1 (en) 2012-07-27 2012-07-27 Derivatives of azaindoles or diazaindoles for treating pain
PCT/EP2013/065907 WO2014016433A1 (en) 2012-07-27 2013-07-29 Derivatives of azaindazole or diazaindazole type for treating pain

Publications (2)

Publication Number Publication Date
CA2879595A1 CA2879595A1 (en) 2014-01-30
CA2879595C true CA2879595C (en) 2020-07-28

Family

ID=48948392

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2879595A Active CA2879595C (en) 2012-07-27 2013-07-29 Derivatives of azaindazole or diazaindazole type for treating pain

Country Status (28)

Country Link
US (1) US9381195B2 (enExample)
EP (2) EP2689778A1 (enExample)
JP (2) JP6456823B2 (enExample)
KR (1) KR102120505B1 (enExample)
CN (1) CN104684554B (enExample)
AU (1) AU2013294920B2 (enExample)
BR (1) BR112015001502B1 (enExample)
CA (1) CA2879595C (enExample)
CY (1) CY1118478T1 (enExample)
DK (1) DK2877177T3 (enExample)
ES (1) ES2612349T3 (enExample)
HR (1) HRP20170104T1 (enExample)
HU (1) HUE032919T2 (enExample)
IL (1) IL236917A (enExample)
LT (1) LT2877177T (enExample)
MA (1) MA37866B1 (enExample)
MX (1) MX363605B (enExample)
MY (1) MY183398A (enExample)
NZ (1) NZ705253A (enExample)
PL (1) PL2877177T3 (enExample)
PT (1) PT2877177T (enExample)
RS (1) RS55646B1 (enExample)
RU (1) RU2640046C2 (enExample)
SI (1) SI2877177T1 (enExample)
TN (1) TN2015000034A1 (enExample)
UA (1) UA116107C2 (enExample)
WO (1) WO2014016433A1 (enExample)
ZA (1) ZA201501209B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264736B (zh) 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
US9573948B2 (en) 2014-10-06 2017-02-21 Flatley Discovery Lab Triazolopyridine compounds and methods for the treatment of cystic fibrosis
TWI746426B (zh) 2014-11-16 2021-11-21 美商亞雷生物製藥股份有限公司 (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
UA125026C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ
UA125025C2 (uk) 2016-04-04 2021-12-29 Локсо Онколоджі, Інк. Способи лікування дитячих ракових захворювань
MX392604B (es) 2016-05-18 2025-03-24 Array Biopharma Inc Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo.
WO2018049271A1 (en) * 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018079759A1 (ja) * 2016-10-31 2018-05-03 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する縮合複素環および縮合炭素環誘導体
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3098988A1 (en) * 2018-05-02 2019-11-07 Jw Pharmaceutical Corporation Heterocycle derivative
KR102129114B1 (ko) * 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
CN110105356B (zh) * 2019-05-31 2022-04-01 四川国康药业有限公司 一种氮杂吲哚类化合物及其制备方法和用途
KR20250173578A (ko) * 2023-05-24 2025-12-10 장춘 진사이언스 파마슈티컬 씨오., 엘티디. Fgfr2/3 선택적 억제제, 약학 조성물 및 이의 용도
WO2026108988A1 (zh) * 2024-11-22 2026-05-28 长春金赛药业有限责任公司 一种成纤维细胞生长因子受体抑制剂化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808281A (pt) * 1997-03-19 2000-05-16 Basf Ag Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
YU93902A (sh) 2000-06-22 2005-11-28 Pfizer Products Inc. Postupak za pripremanje pirazolopirimidinona
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
EP1919913A2 (en) * 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
WO2008010964A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
WO2008074749A1 (en) 2006-12-20 2008-06-26 Nerviano Medical Sciences S.R.L. Indazole derivatives as kinase inhibitors for the treatment of cancer
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
WO2010069966A1 (en) 2008-12-18 2010-06-24 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain

Also Published As

Publication number Publication date
CY1118478T1 (el) 2017-07-12
WO2014016433A1 (en) 2014-01-30
JP2015522650A (ja) 2015-08-06
AU2013294920B2 (en) 2017-08-24
HK1207302A1 (en) 2016-01-29
MY183398A (en) 2021-02-18
HRP20170104T1 (hr) 2017-03-24
UA116107C2 (uk) 2018-02-12
SI2877177T1 (sl) 2017-02-28
BR112015001502A2 (pt) 2017-07-04
MA37866B1 (fr) 2016-12-30
JP2019031542A (ja) 2019-02-28
KR20150038295A (ko) 2015-04-08
ZA201501209B (en) 2016-03-30
IL236917A (en) 2016-11-30
MX2015001009A (es) 2015-06-04
JP6456823B2 (ja) 2019-01-23
DK2877177T3 (en) 2017-02-06
LT2877177T (lt) 2017-01-25
JP6732855B2 (ja) 2020-07-29
EP2877177B1 (en) 2016-10-26
AU2013294920A1 (en) 2015-03-12
EP2689778A1 (en) 2014-01-29
KR102120505B1 (ko) 2020-06-08
PT2877177T (pt) 2017-02-06
HUE032919T2 (hu) 2017-11-28
MA37866A1 (fr) 2016-05-31
NZ705253A (en) 2017-05-26
US9381195B2 (en) 2016-07-05
PL2877177T3 (pl) 2017-04-28
BR112015001502B1 (pt) 2023-03-07
CN104684554B (zh) 2017-05-10
RU2640046C2 (ru) 2017-12-26
MX363605B (es) 2019-03-26
CN104684554A (zh) 2015-06-03
US20150190394A1 (en) 2015-07-09
RU2015106434A (ru) 2016-09-20
TN2015000034A1 (en) 2016-06-29
EP2877177A1 (en) 2015-06-03
ES2612349T3 (es) 2017-05-16
CA2879595A1 (en) 2014-01-30
RS55646B1 (sr) 2017-06-30

Similar Documents

Publication Publication Date Title
JP6732855B2 (ja) 疼痛を治療するためのアザインダゾールまたはジアザインダゾール型の誘導体
EP2668184B1 (en) Derivatives of azaindazole or diazaindazole type as medicament
EP2877176B1 (en) Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
HK1207302B (en) Derivatives of azaindazole or diazaindazole type for treating pain
OA17324A (en) Derivatives of azaindazole or diazaindazole type for treating pain.
OA16493A (en) Derivatives of azaindazole or diazaindazole type as medicament.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180723

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250625

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260625